other material
confidence high
sentiment positive
materiality 0.75
Adicet prioritizes ADI-001 for autoimmunity; closes MCL enrollment; reports 80% ORR, 60% CR
Adicet Bio, Inc.
- Focuses ADI-001 development on four autoimmune indications: lupus nephritis, SLE, systemic sclerosis, ANCA vasculitis.
- Closed Phase 1 MCL enrollment; topline results: ORR 80% (8/10), CR 60% (6/10), median CR duration 17.5 months as of Aug 22, 2024.
- Patients heavily pretreated (median 3 prior therapies); 30% had progressed on prior CAR T; no GvHD, low grade ≥3 CRS/neurotoxicity.
- Plans to present translational data from Phase 1 NHL study at CAR-TCR Summit on Sept 19, 2024 in Boston.
- Expects to expand ADI-001 clinical development into additional autoimmune indications near term.